Breaking News

Galapagos Acquires Cangenix

January 15, 2013

Enhances drug discovery services, forms new service division

Galapagos NV has acquired Cangenix Ltd. for $1.9 million and a potential further payment of $708.7 million based on the achievement of certain conditions. The acquisition adds a structure-based drug discovery platform to Galapagos’ Argenta service offering. Argenta will integrate all of Cangenix's assets, personnel and service contracts with its capabilities in hit finding and medicinal chemistry. The Cangenix team will join Argenta but will continue to operate the platform in its premises in Canterbury, Kent, UK. Cangenix was formed in 2011 by former Pfizer employees from the Structural Biology and Biophysics group at Pfizer’s Sandwich site.
"We welcome the Cangenix team and their clients to the Galapagos group," said Onno van de Stolpe, chief executive officer of Galapagos. "The assets and expertise of Cangenix really address a growing client need at Argenta. We look forward to extending and expanding this business."
"I am confident that Cangenix's expertise in structure-based drug discovery services will enable Argenta to design better drugs for clients," said Prof David Brown, chief executive officer, Cangenix Ltd.
Additionally, Galapagos’ research site in Zagreb, Croatia (acquired from GSK in 2010) will form a new service division called Fidelta. The new drug discovery service unit will provide chemistry, pharmacology (both in vitro and in vivo), biomarker, toxicology and ADME/PK services, with specific experience in inflammation, infectious, metabolic, and oncology diseases.
Fidelta will be led by Phil Dudfield, who has extensive experience in drug discovery within large pharma and Galapagos. Mr. Dudfield also spent five years running fee-for-service groups at BioFocus, a service division of Galapogos.
"With the creation of a third service division we can offer a broader range of services to our customers," said Mr. van de Stolpe. "With this change we can further strengthen our worldwide leadership position in drug discovery services, ranging from target discovery all the way through to the delivery of preclinical candidates, in key disease areas for our clients."
  • Patheon Furthers Expansion Strategy

    Kristin Brooks, Contract Pharma||January 9, 2017
    Patrick Glaser of Patheon discusses expanded manufacturing capacity, capabilities, and future plans

  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Biopharma CMO Market Trends

    Biopharma CMO Market Trends

    Tim Wright, Editor||June 2, 2016
    Continued strong growth in biopharma industry is being driven by biosimilars